Pennsylvania Xarelto Attorneys

Xarelto (rivaroxaban) is an anticoagulant or blood thinner that is manufactured by Janssen Pharmaceutical and co-marketed by Bayer Healthcare. It is prescribed to prevent blood clots in patients suffering from atrial fibrillation, deep vein thrombosis, pulmonary embolism (blood clots in the lungs), stroke, and patients who are undergoing knee or hip replacement surgery. Xarelto is marketed as being easier to use than warfarin — otherwise known as its brand name, Coumadin — which is also an anticoagulant, though Xarelto is said to not require medical monitoring.

Unfortunately, Xarelto use can lead to dangerous internal bleeding that may result in prolonged hospitalization, blood transfusions and may sometimes even be terminal. There have been numerous reports of fatal injuries as a result of Xarelto use, including severe cerebral hemorrhaging and gastrointestinal bleeding. Some injuries that are closely related to Xarelto include stroke, retinal hemorrhaging, epidural hematoma, intracranial hemorrhaging, gastrointestinal hemorrhaging, adrenal bleeding and a decrease in hemoglobin. We are currently investigating cases where Xarelto users have suffered some type of internal bleeding that has required hospitalization, a blood transfusion and/or related injuries.

Lawsuits filed against Janssen and Bayer allege that Xarelto is directly linked to the adverse reactions above because, in the event that a patient's blood does not properly clot, uncontrollable hemorrhaging may occur at even the slightest of abrasions.

The Food and Drug Administration issued a warning letter in 2013 to Janssen and Bayer, remarking that one of the drug's print advertisements minimized the risks associated with its use and made misleading claims. The FDA specifically noted that the same emphasis that was put on the drug's benefits was not placed on the drug's risks, making it seem as though the risks were of little to no importance for potential patients.

Xarelto litigation follows on the heels of Pradaxa litigation. Pradaxa litigation has totaled more than $650 million here in the United States. And Pradaxa litigation is not yet over. Pradaxa cases still come in daily and we are now in what is considered "Phase 2" of Pradaxa litigation. Some experts are assuming similar numbers for those who were adversely affected by Xarelto.

Contact The Pennsylvania Xarelto Attorneys Today — 866-466-5789

If you have questions about Xarelto and its adverse effects, please call the Pittsburgh products liability attorneys at Caroselli, Beachler & Coleman today for a free consultation at 866-466-5789.